Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Connolly (London, United Kingdom), S. Wort (London, United Kingdom), B. Garfield (London, United Kingdom), A. Crosby (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom), P. Kemp (London, United Kingdom). MiR-1-5p targets TGF-ßR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension. 5045

Member's Comments

No comment yet.

Related content which might interest you: Cold exposure lowered miR-21-5p expression in monocrotaline induced pulmonary artery hypertension. Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 Shroom expression is attenuated in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 147s Year: 2006 Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Effect of eNOS gene overexpression on the vascular reactivity of isolated pulmonary arteries of chronic hypoxic rats Source: Annual Congress 2006 - Taormina 4th ERS Lung Science Conference "hypoxia in lung biology and disease" Year: 2006 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011 Shroom expression is attenuated in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 871-880 Year: 2008 The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Effects of BMPR-II signal transduction in the pulmonary vascular remodeling of monocrotaline induced pulmonary hypertension in rats Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 The PPAR-β/δ agonist GW0742 reverses right venticular hypertrophy in a chronically hypoxic rat model of pulmonary hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Role of NFATc3 in chronic hypoxia induced pulmonary hypertension in neonatal mice Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Lodenafil improves hemodynamics and right ventricular remodeling in monocrotaline-induced model of pulmonary arterial hypertension in rats Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis. Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019